Published in Clin Exp Immunol on May 01, 1975
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. Br J Cancer (1977) 1.18
Natural killer cell regulation - beyond the receptors. F1000Prime Rep (2014) 0.88
Antibody-dependent cellular cytotoxicity to human colon-tumour cells. I. Lack of tumour specificity in a population study. Br J Cancer (1979) 0.84
Cytotoxic activity of human lymphocyte plasma membranes. Clin Exp Immunol (1976) 0.80
Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med (1972) 24.43
The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents. Immunochemistry (1969) 14.31
Contactual lysis of antibody-coated chicken erythrocytes by purified lymphocytes. Cell Immunol (1970) 5.10
The human rosette-forming cell as a marker of a population of thymus-derived cells. J Clin Invest (1972) 4.80
A microassay for cell-mediated immunity. Transplantation (1970) 4.29
Studies of allograft immunity in mice. I. Induction, development and in vitro assay of cellular immunity. Immunology (1970) 4.25
Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen. Br J Cancer (1972) 3.91
Quantitative studies on phytohaemagglutinin-induced cytotoxicity by human lymphocytes against homologous cells in tissue culture. Immunology (1967) 3.87
Cellular immunity against tumor antigens. Adv Cancer Res (1969) 3.70
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest (1972) 3.64
Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery (1968) 3.56
Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J (1969) 3.37
Effect of specific antibody to target cells on their specific and non-specific interactions with lymphocytes. Nature (1968) 2.96
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol (1974) 2.68
Spontaneous regression of primary malignant melanomas with regional metastases. Cancer (1965) 2.15
CYTOTOXIC REACTIONS OF MOUSE ISO-ANTISERA: PRELIMINARY CONSIDERATIONS. Br J Exp Pathol (1964) 2.12
Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res (1973) 2.11
The specificity of surface membrane immunofluorescence in human malignant melanoma. Int J Cancer (1972) 1.75
Immunological enhancement: a study of blocking antibodies. Adv Immunol (1972) 1.59
Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst (1974) 1.36
Serum-mediated inhibition of lymphocyte stimulation by autochthonous human tumors. J Natl Cancer Inst (1971) 1.22
Some recent studies on cellular immunity to human melanomas. Fed Proc (1973) 1.22
Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. Int J Cancer (1973) 1.18
Comparative in vitro studies on effector cell diversity in the cellular immune response to murine sarcoma virus (MSV)-induced tumors in mice. J Immunol (1974) 1.09
Cytotoxic lymphocytes in melanoma patients. Int J Cancer (1972) 1.01
51 Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue-culture cells. Natl Cancer Inst Monogr (1973) 0.99
HL-A antigens in solid tumors. Cancer Res (1973) 0.99
Evaluation of a cell-mediated cytotoxicity assay utilizing 125 iododeoxyuridine-labeled tissue-culture target cells. Natl Cancer Inst Monogr (1973) 0.95
Cellular immunity to nephroblastoma. Int J Cancer (1971) 0.88
Cell-mediated cytotoxicity during rejection and enhancement of allogeneic skin grafts in rats. J Exp Med (1972) 0.86
Apparent HL-A5 deficiency in malignant melanoma. Transplantation (1973) 0.83
Tumor-associated antigens in human malignant melanoma. Yale J Biol Med (1973) 0.82
Lymphocyte toxicity test in clinical melanoma. Eur J Cancer (1975) 0.81
Evidence for cancer-specific angigens in man. Prog Exp Tumor Res (1967) 0.81
Halo naevus--a frustrated malignant maelanoma. Br Med J (1972) 0.78
Regression of primary malignant melanoma associated with a good prognosis despite metastasis to lymph nodes. Rev Eur Etud Clin Biol (1970) 0.77
HL-A and malignant melanoma. Lancet (1973) 0.76
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science (1967) 8.62
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med (1998) 8.24
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol (1982) 5.49
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet (2005) 3.97
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines. Nat New Biol (1972) 3.84
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol (1968) 3.09
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res (1994) 2.96
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69
Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer (1982) 2.51
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol (2003) 2.20
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Comparative study of cultured Burkitt tumor cells by immunofluorescence, autoradiography, and electron microscopy. J Virol (1967) 2.07
Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy (1982) 2.06
In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum (1997) 1.95
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood (1998) 1.93
Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol (1984) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis (2003) 1.75
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol (2006) 1.74
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol (2001) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur J Nucl Med (1997) 1.66
Joint and connective tissue ultrasonography--a rheumatologic bedside procedure? A German experience. Arthritis Rheum (1995) 1.66
Meta-analysis: randomized controlled trials of 4-L polyethylene glycol and sodium phosphate solution as bowel preparation for colonoscopy. Aliment Pharmacol Ther (2010) 1.65
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis (2001) 1.63
The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol (2001) 1.62
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol (2004) 1.62
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
SLE--a disease of clearance deficiency? Rheumatology (Oxford) (2005) 1.59
Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Br J Rheumatol (1998) 1.56
Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol (1993) 1.55
Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum (1993) 1.53
Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol (1990) 1.52
Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) (2000) 1.52
Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep (1982) 1.51
Transient hypogammaglobulinemia of infancy: Five new cases, review of the literature and redefinition. Acta Paediatr Scand (1989) 1.51
Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol (1981) 1.50
Studies on experimental autoimmune thymitis in guinea-pigs. Clin Exp Immunol (1969) 1.50
Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol (1995) 1.50
Magnetic resonance imaging (MRI) for detection of active sacroiliitis--a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol (1996) 1.49
Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol (1992) 1.48
In vitro and in vivo effect of glucocorticoids on IgE and IgG subclass secretion. Clin Exp Allergy (1994) 1.47
Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol Oncol (1984) 1.47
Type II collagen-specific human T cell lines established from healthy donors. Eur J Immunol (1990) 1.47
Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. Eur J Immunol (1996) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation (2001) 1.46
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum (1991) 1.45
CD4 positive peripheral T cells from patients with systemic lupus erythematosus (SLE) are clonally expanded. Lupus (2001) 1.44
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol (2011) 1.44
C-group chromosome marker in long-term leukocyte cultures. J Natl Cancer Inst (1968) 1.43
Hodgkin's disease--environmental or genetic? N Engl J Med (1995) 1.43
Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. Am J Clin Nutr (1999) 1.42
STAT3 is constitutively activated in Hodgkin cell lines. Blood (2001) 1.42
Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med (2000) 1.40
Correlation of chromosomal aberrations in a myeloma cell line with tumorigenicity in nude mice. Blut (1981) 1.40
Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med (2000) 1.40
Intravascular coagulation necrosis of the skin associated with cryofibrinogenemia, diabetes mellitus, and cardiolipin autoantibodies. J Am Acad Dermatol (1991) 1.39
Posttraumatic reflex sympathetic dystrophy anteceding inverse psoriasis and psoriatic arthritis. J Rheumatol (1995) 1.39
Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol (2000) 1.39
High platelet contamination in progenitor cell concentrates results in significantly lower CD34+ yield after immunoselection. Transfusion (2000) 1.39
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis (2002) 1.39
Resting energy expenditure, weight loss, and altered body composition in HIV infection. Nutrition (1996) 1.38
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol (2000) 1.33
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. J Immunol (2000) 1.32